ClinicaliQ Trial Snapshot
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of….
- What is being tested: Finerenone (a non-steroidal mineralocorticoid receptor antagonist) safety and tolerability in children and young adults aged 1-18 years with chronic kidney disease and proteinuria, administered alongside standard ACE inhibitor or angiotensin receptor blocker therapy over 18 months.
- Patient eligibility overview: Children and young adults aged 1-18 years with confirmed chronic kidney disease who have proteinuria (urinary protein loss) and are already established on ACE inhibitor or ARB treatment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine. The kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood pressure, also known…
Eligibility Snapshot
- : * Participants must be ≥1 year to 18 years of age, at the time of signing the informed consent/assent. * Prior participation in the finerenone Phase 3 study FIONA (19920) and not permanently discontinued from treatment by the end of treatment (EoT) visit in FIONA. * Participants must have a clinical diagnosis of chronic kidney disease (CKD) at Visit 1 which is defined as * CKD stages 1-3 (estimated glomerular filtration rate [eGFR] ≥30 mL/min/1.73m^2) for children ≥1 year to
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.